UBS assumed coverage of Pfizer with a Neutral rating and price target of $34, down from $36. While Pfizer screens well on valuation with some investors sensing a potential trough, it is tough to turn sentiment around given a lack of meaningful catalysts on the horizon, continuing uncertainty over COVID, and less business development optionality post-Seagen, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE:
- Pfizer (NYSE:PFE) Dips as UBS Starts Coverage
- LLY vs. PFE: Which Pharma Stock is the Better Buy?
- Alphabet Stock (NASDAQ:GOOGL) Q3 Earnings Preview: Can Its Strength be Sustained?
- Pfizer (NYSE:PFE) Slides despite EU Nod to Seagen Acquisition
- Pfizer receives unconditional approval for Seagen acquisition from EU